A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 12024 participants.

Also called NCT02111564

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 12,024 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02111564
  • EudraCT 2014-000305-13
Other papers using this trial's data
  • Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness Journal of the American Heart Association, 2022-10-18 DOI, PubMed 36205248, PMC9673674 In the PMC Open Access subset under CC BY-NC.
  • Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients Journal of the American College of Cardiology, 2020-06-30 DOI, PubMed 32586587, PMC7308003 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness The New England journal of medicine, 2018-09-20 DOI, PubMed 30145946

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belarus, Bosnia & Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Estonia, Georgia, Germany, Greece, Hungary, Israel, Latvia, Lithuania, Mexico, Netherlands, North Macedonia, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02111564. Randomized; double masking; primary purpose prevention. Start 2014-01-07 (actual); primary completion 2018-03-06 (actual). Results posted on 2019-11-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Acronym
MARINER
Condition
Heart Failure
Condition
Respiratory Insufficiency
Condition
Stroke Acute
Condition
Infectious Diseases
Condition
Rheumatic Diseases
Intervention (Drug)
Rivaroxaban, 10 mg
Intervention (Drug)
Rivaroxaban, 7.5 mg
Intervention (Drug)
Placebo
Lead sponsor
Janssen Research & Development, LLC (class: industry)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02111564
Content hash
9c53521ec43cbd92e54370e8dd59bc920ff74d09e80e1b1312f76376f0352bcd